Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics for Alvelestat

Mereo BioPharma Group plc (NASDAQ: MREO) has entered into an Option and License Agreement with Sentynl Therapeutics, Inc. for the U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Under the agreement, Mereo will receive a non-refundable option fee and is eligible for significant upfront, R&D, and milestone payments, plus double-digit tiered royalties on U.S. sales.